GUT MICROBIOME IN IRRITABLE BOWEL SYNDROME: FOUNDATION FORPERSONALIZED MICROBIOME CORRECTION

Підписуйтесь на наші соціальні мережі, щоб стежити за останніми новинами тут 💜:

Сайт: www.ediens.me

Facebook: www.facebook.com/profile.php?id=61561258499410  

LinkedIn: www.linkedin.com/ediens 

Instagram: www.instagram.com/ediens_official

TikTok: www.tiktok.com/@ediens_official 

UEG2025: 2567

S. Burmei , L. Yusko , O. Pallah , N. Boyko

Uzhhorod National University, Uzhhorod, Ukraine, Ediens, Uzhhorod, Ukraine

Abstract selection

General data

Topic: 6.13.: Irritable bowel syndrome: Classification and diagnosis

Title

Abstract body

Introduction: An in-depth analysis of the gut microbiota plays a crucial role in modern research exploring the relationship between

intestinal microorganisms and human health. The use of molecular-genetic methods, particularly next-generation sequencing (NGS),

provides a comprehensive understanding of the structural and functional characteristics of microbial ecosystems associated with the

development of gastrointestinal pathologies.

Aims & Methods: To assess the features of the gut microbiome composition in different clinical variants of irritable bowel syndrome

(IBS) in order to establish a foundation for microbiome-targeted personalized therapy. The study included 100 fecal samples, 90 from

individuals with clinically confirmed IBS, and 10 samples from relatively healthy volunteers who formed the control group. The

average age of participants was 55±2.23 years. DNA extraction from the samples was performed using the ZymoBIOMICS DNA Mini

Kit according to the official protocol. Taxonomic identification was conducted based on 16S rRNA gene amplification, which is

considered the gold standard in phylogenetic studies of prokaryotes.

Results: The analysis revealed clear differences in the microbial composition between IBS subtypes and the control group.

Specifically, for IBS-D (diarrhea-predominant type): the Firmicutes to Bacteroidetes ratio shifted towards Firmicutes (55.5% to 32.4%),

indicating dysbiosis characteristic of metabolic disorders. For IBS-C (constipation-predominant type), a decrease in Bacteroidetes to

34% and an increase in Firmicutes to 52% were noted, which is associated with an increased risk of obesity and insulin resistance. In

IBS-M (mixed type): partial stability of the microbial profile was observed, but with a predominance of Firmicutes (53%), possibly

indicating altered intestinal motility. In all clinical variants of IBS, microbial imbalance, reduced production of short-chain fatty acids,

weakened mucosal barrier, and increased endotoxin activity of the microbiota were recorded. Additionally, a potential impact on the

neuropsychological status of patients was traced, supporting the connection between the gut microbiome and the central nervous

system.

Conclusion: The identified microbiome disturbances in various forms of IBS highlight the need for an individualized therapeutic

approach, including diet therapy, the use of probiotic and prebiotic supplements, as well as promising pharmabiotics. A promising

direction is the implementation of personalized microbiome corrections based on the patient’s metagenomic profile.

References

Disclosure

Nothing to disclose: Yes

Keywords

Keyword 1: irritable bowel syndrome

Keyword 2: microbiome

Keyword 3: personalized

General conditions

1. I have read and I accept the Privacy Policy and General Terms and Conditions: Yes

2. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract

cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as

submitted.: Yes

3. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website,

programmes, other promotions, etc.).: Yes

4. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be

notified about the status of the abstract. The corresponding author is responsible for informing the other authors

about the status of the abstract.: Yes

Questions

1,2 1 1 1,2

1 2

Has this abstract been presented at a national meeting?: No

Has this abstract been presented at DDW/AGA/AASLD?: No

Has this abstract been presented at another international meeting?: No

Has this abstract been previously published?: No

Questions for Abstract

This abstract should be considered as Translational/Basic Science abstract : No

Questions for Abstract and LB

This abstract should be taken into consideration for the ’Hot topics in precision medicine’ abstract sessions. : Yes

This abstract should be considered as Paediatric abstract : No

Travel grant application

Travel grant application: No